Clinical Trial

99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
An open-label, single-center study with 99mTc-1-thio-D-glucose single photon emission computed tomography / computed tomography (SPECT/CT) and 18F-fluoroethyl-l-tyrosine (18F-FET) positron emission tomography / computed tomography (PET/CT) in primary and recurrent glioma patients, where the primary endpoint of the study is to compare imaging properties of 99mTc-1-thio-D-glucose SPECT/CT and 18F-FET PET/CT of brain tumor Imaging.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-11; most recent amendment 2026-06-23.
Trial Details
NCT Number NCT07475390
Lead Sponsor Tomsk National Research Medical Center of the Russian Academy of Sciences
Conditions Glioma (Any Grade) in the Brain
Enrollment 40 participants
Start Date 2026-02-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24